Methods and compositions for treatment of bone defects with placental cell populations
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-035/50
A61K-009/00
A61K-047/36
A61K-047/42
C12N-005/0775
A61L-027/38
C12N-005/073
C12N-005/077
A61K-035/12
출원번호
US-0093185
(2016-04-07)
등록번호
US-10105399
(2018-10-23)
발명자
/ 주소
Edinger, James W.
Hariri, Robert J.
Wang, Jia-Lun
Ye, Qian
Labazzo, Kristen S.
Pereira, Marian
Abramson, Sascha Dawn
출원인 / 주소
CELULARITY, INC.
대리인 / 주소
Smith, Timothy L.
인용정보
피인용 횟수 :
0인용 특허 :
65
초록▼
Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the place
Provided herein are methods of using adherent placental stem cells and placental stem cell populations, and methods of culturing, proliferating and expanding the same. Also provided herein are methods of differentiating the placental stem cells. Further provided herein are methods of using the placental stem cells to formulate implantable or injectable compositions suitable for administration to a subject. Still further provided herein are provides methods for treating bone defects with stem cells and compositions comprising stem cells.
대표청구항▼
1. A method for treating a bone defect in a subject, wherein said bone defect is an osteolytic lesion associated with multiple myeloma, bone cancer, or metastatic cancer characterized by bone metastases, comprising administering to a subject in need thereof an implantable or injectable composition c
1. A method for treating a bone defect in a subject, wherein said bone defect is an osteolytic lesion associated with multiple myeloma, bone cancer, or metastatic cancer characterized by bone metastases, comprising administering to a subject in need thereof an implantable or injectable composition comprising a population of placental stem cells, wherein said population is predominantly CD34−, CD10+, CD105+, and CD200+;wherein said stem cells express genes at a detectably higher level than an equivalent number of bone marrow-derived mesenchymal stem cells (BM-MSCs);and wherein said genes comprise CPA4, TCF21, VTN, B4GALT6, FLJ10781, or NUAK1; thereby treating the bone defect in the subject. 2. The method of claim 1, wherein said placental stem cells have been passaged at least six times. 3. The method of claim 1, wherein said population is predominantly CD34−, CD45−, CD10+, CD90+, CD105+, and CD200+. 4. The method of claim 1, wherein said placental stem cells comprise at least 70% of cells in said composition. 5. The method of claim 1, wherein said placental stem cells comprise at least 90% of cells in said composition. 6. The method of claim 1, wherein said osteolytic lesion is an osteolytic lesion associated with multiple myeloma. 7. The method of claim 1, wherein said osteolytic lesion is an osteolytic lesion associated with bone cancer. 8. The method of claim 1, wherein said osteolytic lesion is an osteolytic lesion associated with metastatic cancer. 9. The method of claim 1, wherein said placental stem cells are cells from a placental stem cell bank. 10. The method of claim 1, wherein said composition is formulated as a suspension or liquid that can be administered intravenously. 11. The method of claim 1, wherein said composition comprises 5×106 said placental stem cells per milliliter. 12. The method of claim 1, wherein said composition comprises an implantable substrate or matrix. 13. The method of claim 1, wherein said composition comprises human serum albumin (HSA) and dextran-40. 14. The method of claim 1, wherein said placental stem cells are autologous to said subject. 15. The method of claim 1, wherein said placental stem cells have been cryopreserved. 16. The method of claim 1, wherein said population is predominantly CD73+. 17. The method of claim 16, wherein at least 80% of the placental stem cells in said population are CD73+, CD105+, and CD200+. 18. The method of claim 16, wherein at least 90% of the placental stem cells in said population are CD73+, CD105+, and CD200+. 19. The method of claim 1, wherein said population has been passaged at least three times. 20. The method of claim 19, wherein said population has been passaged no more than ten times.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (65)
Pittenger Mark F., Adipogenic differentiation of human mesenchymal stem cells.
Heidaran, Mohammad; Wang, Jia-Lun; Ye, Qian; Zeitlin, Andrew; Delaney, Colleen Suzanne, Co-culture of placental stem cells and stem cells from a second source.
Heidaran, Mohammad; Wang, Jia-Lun; Ye, Qian; Zeitlin, Andrew; Dulaney, Colleen Suzanne, Co-culture of placental stem cells and stem cells from a second source.
Janice M. Davis-Sproul ; Mark Aaron Moorman ; Renee Marie McNeil ; Donald William Simonetti, Jr. ; Lora Catherine Hammill ; Stewart Craig, Human mesenchymal stem cells.
Prockop Darwin J. ; Pereira Ruth F. ; Leeper Dennis B. ; O'Hara Michael D., Isolated stromal cells for treating diseases, disorders or conditions characterized by bone defects.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for enhancing the implantation and differentiation of marrow-derived mesenchymal cells.
Caplan Arnold I. (1300 Oakridge Dr. Cleveland Heights OH 44121) Haynesworth Stephen E. (3643 Antisdale Rd. Cleveland Heights OH 44118), Method for treating connective tissue disorders.
Edinger, James W.; Hariri, Robert J.; Wang, Jia-Lun; Ye, Qian; Labazzo, Kristen S.; Pereira, Marian; Abramson, Sascha Dawn, Methods and compositions for treatment of bone defects with placental cell populations.
Edinger, James W.; Hariri, Robert J.; Wang, Jia-Lun; Ye, Qian; Labazzo, Kristen S.; Pereira, Marian; Abramson, Sascha Dawn, Methods and compositions for treatment of bone defects with placental cell populations.
Hariri, Robert J.; Stirling, David I.; Moutouh-De Parseval, Laure A.; Chan, Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
Hariri,Robert J.; Stirling,David I.; Moutouh De Parseval,Laure A.; Chan,Kyle W. H., Modulation of stem and progenitor cell differentiation, assays, and uses thereof.
McIntosh, Kevin; Klyushnenkova, Elena, Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation.
Paludan, Casper; Edinger, James W.; Harbacheuski, Ryhor; Murray, RoseAnn; Hariri, Robert J., Treatment of multiple sclerosis using placental stem cells.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.